Current Immunotherapy and Targeted Therapy Standard of Care in Biliary Tract Cancer: Dabrafenib-Trametinib for BRAF+, Infigratinib for FGFR+, Ivsidenib for IDH-1, and Pembro for MSI-H Tumors
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Fatih Kose
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Fatih Kose
Comments 0
Login to view comments.
Click here to Login
